Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Researchers Uncover a Hidden Trigger Behind Chronic Inflammation (opens in a new tab)

scitechdaily.com · 2026-09-16

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study.

  • 3 supported
  • 2 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Two of five claims overstate the study. Three of five check out.

  • 3 supported
  • 2 overstated
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedHuman resistin may help flip on one of the immune system’s most powerful inflammatory switches by activating a pathway involved in chronic inflammation.View evidenceHide evidence

As statedone of the immune system’s most powerful inflammatory switches

Why this verdict

The abstract-level profile supports the core idea that human resistin can prime and activate the NLRP3 inflammasome in macrophages. However, the headline framing adds an unquantified superlative—“one of the immune system’s most powerful inflammatory switches”—that is not established in the supplied paper profile. The hedging “may help” is appropriate, but the headline’s magnitude language outruns the abstract evidence and the more specific body framing.

1

Study evidence

hResistin exposure of human macrophages increased HMGB1 expression and secretion and primed increased expression of NLRP3, pro‑caspase‑1, pro‑IL‑1β, and pro‑IL‑18, based on qPCR and western blot measurements reported in the abstract.

“Through qPCR and western blot analysis, we found that hResistin-dependent expression and secretion of high mobility group box 1 (HMGB1) in human macrophages primes the expression of NLRP3, pro-caspase-1, pro-interleukin(IL)-1β, and pro-IL-18.”
2

Study evidence

hResistin associates with Bruton's tyrosine kinase (BTK) in human macrophages as detected by co-immunoprecipitation.

“Co-immunoprecipitation showed that hResistin binds to Bruton's tyrosine kinase (BTK), which causes the kinase to autophosphorylate.”
Claim 2 of 5OverstatedLung tissue from patients with pulmonary hypertension showed increased activity of both resistin and the inflammasome pathway.View evidenceHide evidence

Why this verdict

The paper profile supports an ex vivo human PH lung finding: most NLRP3-expressing cells were macrophages, and colocalization of hResistin, BTK, and NLRP3 in macrophages was increased in PH patient lungs. The story’s wording that lung tissue showed increased “activity” of resistin and the inflammasome pathway overstates this evidence, because immunohistochemistry/colocalization is correlative and does not by itself demonstrate pathway activity or functional activation in patient tissue.

1

Study evidence

In human pulmonary hypertension lung specimens, most NLRP3-expressing cells were macrophages.

“Immunohistochemistry revealed that the majority of NLRP3-expressing cells were macrophages and the colocalization of hResistin, BTK, and NLRP3 in macrophages was increased in PH patients' lungs.”
Claim 3 of 5SupportedResearchers at Johns Hopkins Medicine found that resistin can activate the NLRP3 inflammasome pathway involved in chronic inflammation, a process linked to cardiovascular disease, diabetes, and autoimmune disorders.View evidenceHide evidence

Why this verdict

The supplied abstract profile supports that Johns Hopkins Medicine researchers found human resistin can activate the NLRP3 inflammasome pathway in macrophage experiments, including priming and BTK/NLRP3 activation mechanisms. The specific examples of cardiovascular disease, diabetes, and autoimmune disorders are not independently detailed in the abstract-level profile, but the paper does frame the pathway as relevant to inflammatory disease rather than as proven clinical causation in those conditions.

1

Study evidence

hResistin exposure of human macrophages increased HMGB1 expression and secretion and primed increased expression of NLRP3, pro‑caspase‑1, pro‑IL‑1β, and pro‑IL‑18, based on qPCR and western blot measurements reported in the abstract.

“Through qPCR and western blot analysis, we found that hResistin-dependent expression and secretion of high mobility group box 1 (HMGB1) in human macrophages primes the expression of NLRP3, pro-caspase-1, pro-interleukin(IL)-1β, and pro-IL-18.”
2

Study evidence

hResistin associates with Bruton's tyrosine kinase (BTK) in human macrophages as detected by co-immunoprecipitation.

“Co-immunoprecipitation showed that hResistin binds to Bruton's tyrosine kinase (BTK), which causes the kinase to autophosphorylate.”
Claim 4 of 5SupportedThe study found that resistin helps prepare macrophages for an inflammatory response and then helps activate the NLRP3 inflammasome itself.View evidenceHide evidence

Why this verdict

This matches the paper profile: hResistin primes macrophages for NLRP3 inflammasome component expression via an HMGB1-related priming step and then promotes NLRP3 inflammasome activation through a BTK–NLRP3 mechanism. The evidence is abstract-level and mainly in vitro, but the claim is about the study’s mechanistic findings and is supported.

1

Study evidence

hResistin exposure of human macrophages increased HMGB1 expression and secretion and primed increased expression of NLRP3, pro‑caspase‑1, pro‑IL‑1β, and pro‑IL‑18, based on qPCR and western blot measurements reported in the abstract.

“Through qPCR and western blot analysis, we found that hResistin-dependent expression and secretion of high mobility group box 1 (HMGB1) in human macrophages primes the expression of NLRP3, pro-caspase-1, pro-interleukin(IL)-1β, and pro-IL-18.”
2

Study evidence

hResistin associates with Bruton's tyrosine kinase (BTK) in human macrophages as detected by co-immunoprecipitation.

“Co-immunoprecipitation showed that hResistin binds to Bruton's tyrosine kinase (BTK), which causes the kinase to autophosphorylate.”
Claim 5 of 5SupportedUsing a targeted antibody against resistin reduced activation of the pathway.View evidenceHide evidence

Why this verdict

The supplied profile supports that blocking hResistin with a human monoclonal antibody inhibited NLRP3 inflammasome activation and reduced downstream IL-1β/IL-18 secretion in macrophage assays. The story’s wording is consistent so long as it is understood as an in vitro pathway-activation experiment, not demonstrated clinical efficacy.

1

Study evidence

Application of a human monoclonal antibody against hResistin inhibited activation of the NLRP3 inflammasome and decreased secretion of IL-1β and IL-18 in macrophage assays.

“Inhibiting NLRP3 activation by blocking hResistin with a human monoclonal antibody suggests a likely therapeutic pathway for NLRP3-driven inflammatory diseases.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Macrophage-derived IL-1β and IL-18 downstream of hResistin/NLRP3 activation were reported as critical for proliferation of human pulmonary vascular smooth muscle cells.

    This secondary functional contribution is not represented in the supplied story presentation. It is material because it connects macrophage inflammasome activation to a disease-relevant vascular-cell outcome.

    From in vitro

  • In a mouse chronic hypoxia pulmonary hypertension model, RELMα was required for hypoxia-induced upregulation of HMGB1, BTK, and NLRP3 in lung tissue and was linked to vascular remodeling pathways.

    The story presentation mentions human PH lung tissue but does not mention the mouse in vivo RELMα knockout/hypoxia corroboration. This is a material paper element supporting in vivo relevance.

    From In vivo chronic hypoxia PH model; RELMα KO vs wild-type comparison; human lung immunohistochemistry

  • Key translational limitation: the main macrophage mechanism and antibody-blockade findings are in vitro, and the human PH lung evidence is descriptive/correlative rather than proof of in-patient mechanism or clinical benefit.

    The story says the work may guide future therapies and notes that the lung-tissue finding reinforces relevance rather than proving clinical benefit, but it does not clearly convey that the central mechanistic and antibody data are in vitro and that the human tissue data are colocalization/correlation only. This is an interpretation-changing limitation.

    From in vitro macrophage stimulation; In vitro human macrophage co-immunoprecipitation and phospho-/cleavage western assays;

4 things the story did carry across
  • Human resistin primes macrophage NLRP3 inflammasome components, reported via HMGB1 expression/secretion and increased NLRP3, pro-caspase-1, pro-IL-1β, and pro-IL-18 in human macrophage cultures.
  • Human resistin activates the NLRP3 inflammasome through a BTK-related mechanism involving hResistin–BTK association, BTK autophosphorylation, NLRP3 phosphorylation, inflammasome assembly/activation, and cytokine cleavage.
  • Human pulmonary hypertension lung specimens showed macrophage localization of NLRP3-expressing cells and increased colocalization of hResistin, BTK, and NLRP3 in macrophages.
  • Blocking human resistin with a human monoclonal antibody inhibited NLRP3 activation in macrophage assays, suggesting a possible therapeutic pathway for NLRP3-driven inflammatory diseases.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroHuman resistin (and rodent RELMα) primes and activates the NLRP3 inflammasome in macrophages via an HMGB1-priming step and a BTK–NLRP3 activation mechanism.in vitro macrophage stimulationExpand

In plain English

In human macrophage cultures, exposure to human resistin (hResistin) increased expression and secretion of HMGB1 and thereby primed increased expression of NLRP3 and the inflammasome pro‑components pro‑caspase‑1, pro‑IL‑1β, and pro‑IL‑18, as measured by qPCR and western blot.

Key findings

  • hResistin exposure of human macrophages increased HMGB1 expression and secretion and primed increased expression of NLRP3, pro‑caspase‑1, pro‑IL‑1β, and pro‑IL‑18, based on qPCR and western blot measurements reported in the abstract.
“Through qPCR and western blot analysis, we found that hResistin-dependent expression and secretion of high mobility group box 1 (HMGB1) in human macrophages primes the expression of NLRP3, pro-caspase-1, pro-interleukin(IL)-1β, and pro-IL-18.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vitroHuman resistin (and rodent RELMα) primes and activates the NLRP3 inflammasome in macrophages via an HMGB1-priming step and a BTK–NLRP3 activation mechanism.In vitro human macrophage co-immunoprecipitation and phospho-/cleavage western assaysExpand

In plain English

In human macrophage experiments, hResistin associates with Bruton's tyrosine kinase (BTK), induces BTK autophosphorylation, and through BTK-dependent phosphorylation of NLRP3 promotes NLRP3 inflammasome assembly and activation as indicated by caspase-1, IL-1β, and IL-18 cleavage.

Key findings

  • hResistin associates with Bruton's tyrosine kinase (BTK) in human macrophages as detected by co-immunoprecipitation.
  • hResistin treatment is associated with BTK autophosphorylation in human macrophages.
“Co-immunoprecipitation showed that hResistin binds to Bruton's tyrosine kinase (BTK), which causes the kinase to autophosphorylate.”
What this piece can’t prove
  • Abstract does not specify experiments that test necessity and sufficiency of BTK for NLRP3 phosphorylation (e.g., BTK inhibition, genetic knockdown/rescue, or in vitro kinase assays).

2 further details could not be confirmed from the summary.

3in vitroDownstream, hResistin-dependent inflammasome cytokines (IL-1β/IL-18) from macrophages promote proliferation of human pulmonary vascular smooth muscle cells (PVSMCs).Expand

In plain English

In vitro evidence reported in the abstract indicates that hResistin-driven activation of the macrophage NLRP3 inflammasome leads to secretion of IL-1β and IL-18, and that these macrophage-derived cytokines were required for proliferation of human pulmonary vascular smooth muscle cells (PVSMCs).

Key findings

  • hResistin-dependent activation and secretion of IL-1β and IL-18 from macrophages were critical to proliferation of human pulmonary vascular smooth muscle cells.
“The hResistin-dependent activation and secretion of IL-1β and IL-18 were critical to the proliferation of human pulmonary vascular smooth muscle cells.”
What this piece can’t prove
  • Description is limited to the abstract; key experimental details (assay type, controls, sample size, statistics) are missing.
  • In vitro PVSMC model may not fully recapitulate in vivo vascular remodeling processes.

2 further details could not be confirmed from the summary.

4in vivo animalIn vivo and human-disease corroboration: RELMα is required for hypoxia-induced pulmonary hypertension molecular changes in mice, and hResistin/BTK/NLRP3 colocalize in macrophages in lungs from pulmonary hypertension patients.In vivo chronic hypoxia PH model; RELMα KO vs wild-type comparison; human lung immunohistochemistryExpand

In plain English

In a chronic hypoxia–induced mouse model of pulmonary hypertension, RELMα was required for hypoxia-dependent upregulation of HMGB1, BTK, and NLRP3 in lung tissue and was linked to vascular remodeling pathways; immunohistochemistry of human PH lungs showed that most NLRP3-expressing cells were macrophages and that colocalization of hResistin, BTK, and NLRP3 in macrophages was increased in PH patient lungs.

Key findings

  • RELMα is required for hypoxia-induced upregulation of HMGB1, BTK, and NLRP3 in mouse lung in a chronic hypoxia pulmonary hypertension model.
  • In human pulmonary hypertension lung tissue, the majority of NLRP3-expressing cells were macrophages and colocalization of hResistin, BTK, and NLRP3 in macrophages was increased.
“For confirmation in vivo, we studied rodent… pulmonary hypertension (PH). Chronic hypoxia-induced PH in wild-type and RELMα KO mice showed RELMα-dependent upregulation of HMGB1, BTK, and NLRP3 in mouse lung and RELMα was linked to vascular remodeling pathways.”
What this piece can’t prove
  • Abstract does not report whether RELMα knockout altered functional PH outcomes (hemodynamic measures or extent of vascular remodeling) beyond molecular associations.

3 further details could not be confirmed from the summary.

5ex vivo humanIn vivo and human-disease corroboration: RELMα is required for hypoxia-induced pulmonary hypertension molecular changes in mice, and hResistin/BTK/NLRP3 colocalize in macrophages in lungs from pulmonary hypertension patients.ex vivo human tissue immunohistochemistry / colocalization analysisExpand

In plain English

Immunohistochemical analysis of human pulmonary hypertension (PH) lung specimens found that most NLRP3-expressing cells were macrophages and that colocalization of human resistin (hResistin), Bruton's tyrosine kinase (BTK), and NLRP3 in macrophages was increased in lungs from PH patients.

Key findings

  • In human pulmonary hypertension lung specimens, most NLRP3-expressing cells were macrophages.
  • Colocalization of hResistin, BTK, and NLRP3 was increased in macrophages from PH patient lungs.
“Immunohistochemistry revealed that the majority of NLRP3-expressing cells were macrophages and the colocalization of hResistin, BTK, and NLRP3 in macrophages was increased in PH patients' lungs.”
What this piece can’t prove
  • Abstract provides no details on number of human specimens, patient selection, or quantitative/ statistical analyses.
  • Immunohistochemistry/colocalization cannot establish causality or direct protein–protein interactions.

1 further detail could not be confirmed from the summary.

6in vitroTherapeutic implication: blocking hResistin with a human monoclonal antibody inhibits NLRP3 activation.in vitro monoclonal antibody blockadeExpand

In plain English

In human macrophage assays, blockade of human resistin (hResistin) with a human monoclonal antibody inhibited NLRP3 inflammasome activation and downstream IL-1β and IL-18 secretion, which the authors propose as a potential therapeutic approach for NLRP3-driven inflammatory diseases.

Key findings

  • Application of a human monoclonal antibody against hResistin inhibited activation of the NLRP3 inflammasome and decreased secretion of IL-1β and IL-18 in macrophage assays.
“Inhibiting NLRP3 activation by blocking hResistin with a human monoclonal antibody suggests a likely therapeutic pathway for NLRP3-driven inflammatory diseases.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 37 candidate papers

Candidate

Hepatic transcriptomic landscape of chicken reveals host responses to spotty liver disease

PLOS One · 2026 · Crossref

Source (opens in a new tab)

And 31 more candidates considered.